These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 10908764)

  • 1. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency.
    Krantz DA; Hallahan TW; Orlandi F; Buchanan P; Larsen JW; Macri JN
    Obstet Gynecol; 2000 Aug; 96(2):207-13. PubMed ID: 10908764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities.
    Nicolaides KH
    Am J Obstet Gynecol; 2004 Jul; 191(1):45-67. PubMed ID: 15295343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
    Spencer K; Nicolaides KH
    BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-trimester screening for trisomies 21 and 18.
    Wapner R; Thom E; Simpson JL; Pergament E; Silver R; Filkins K; Platt L; Mahoney M; Johnson A; Hogge WA; Wilson RD; Mohide P; Hershey D; Krantz D; Zachary J; Snijders R; Greene N; Sabbagha R; MacGregor S; Hill L; Gagnon A; Hallahan T; Jackson L;
    N Engl J Med; 2003 Oct; 349(15):1405-13. PubMed ID: 14534333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
    von Kaisenberg CS; Gasiorek-Wiens A; Bielicki M; Bahlmann F; Meyberg H; Kossakiewicz A; Pruggmayer M; Kamin G; Fritzer E; Harris C; Arnold N;
    J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency.
    Orlandi F; Damiani G; Hallahan TW; Krantz DA; Macri JN
    Ultrasound Obstet Gynecol; 1997 Dec; 10(6):381-6. PubMed ID: 9476320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maternal weight and ethnic adjustment within a first-trimester Down syndrome and trisomy 18 screening program.
    Krantz DA; Hallahan TW; Macri VJ; Macri JN
    Prenat Diagn; 2005 Aug; 25(8):635-40. PubMed ID: 16049986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prenatal screening for fetal aneuploidy in singleton pregnancies.
    Chitayat D; Langlois S; Douglas Wilson R; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
    Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
    Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical use of first-trimester aneuploidy screening in a United States population can replicate data from clinical trials.
    Perni SC; Predanic M; Kalish RB; Chervenak FA; Chasen ST
    Am J Obstet Gynecol; 2006 Jan; 194(1):127-30. PubMed ID: 16389021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-trimester screening for trisomy 21 combining biochemistry and ultrasound at individually optimal gestational ages. An interventional study.
    Borrell A; Casals E; Fortuny A; Farre MT; Gonce A; Sanchez A; Soler A; Cararach V; Vanrell JA
    Prenat Diagn; 2004 Jul; 24(7):541-5. PubMed ID: 15300745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
    Borenstein M; Persico N; Kagan KO; Gazzoni A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jul; 32(1):5-11. PubMed ID: 18512854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluation of a first trimester screening program for Down syndrome and other chromosomal abnormalities using maternal age, nuchal translucency and biochemistry in an Australian population.
    Scott F; Peters H; Bonifacio M; McLennan A; Boogert A; Kesby G; Anderson J
    Aust N Z J Obstet Gynaecol; 2004 Jun; 44(3):205-9. PubMed ID: 15191443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of nuchal translucency in contemporary obstetric practice.
    Said S; Malone FD
    Clin Obstet Gynecol; 2008 Mar; 51(1):37-47. PubMed ID: 18303498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies.
    Avgidou K; Papageorghiou A; Bindra R; Spencer K; Nicolaides KH
    Am J Obstet Gynecol; 2005 Jun; 192(6):1761-7. PubMed ID: 15970804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Hoopmann M; Abele H; Alkier R; Lüthgens K
    Ultrasound Obstet Gynecol; 2012 Nov; 40(5):530-5. PubMed ID: 22611005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study.
    Audibert F; Dommergues M; Benattar C; Taieb J; Thalabard JC; Frydman R
    Ultrasound Obstet Gynecol; 2001 Jul; 18(1):26-31. PubMed ID: 11489221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.